Telix schedules December 1 meeting. Twelve analysts cover Telix stock

Published on 10/27/2026 at 19:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q3 revenue reached USD 245.00 million, up 19.00 percent year over year. Telix stock costs EUR 8.13 on October 27, 2026 at 7:26 p.m. CEST.

Meeting date and revenue update

Telix scheduled its shareholder meeting for December 1, 2026.
Third-quarter revenue reached USD 245.00 million, up 19.00 percent year over year.
Telix stock costs EUR 8.13 at Lang & Schwarz on October 27, 2026 at 7:26 p.m. CEST.
Full-year revenue and other income is expected to exceed USD 1.00 billion.

Telix, AU000000TLX2, Illustration mit AI erstellt.

Telix Pharmaceuticals Limited (AU000000TLX2) scheduled its General Meeting of Shareholders for December 1, 2026, according to Telix Pharmaceuticals. MarketScreener lists 12 analysts in its consensus coverage. Telix stock was trading at EUR 8.13 at Lang & Schwarz on October 27, 2026 at 7:26 p.m. CEST.

December meeting has a date

The shareholder meeting is scheduled for December 1, 2026, in connection with Telix's corporate agenda. The date follows the company's third-quarter update, which also described the proposed ITM merger and its remaining shareholder approval process. The official release dated October 21, 2026, said the transaction includes USD 1.65 billion of upfront consideration and approximately USD 1.25 billion in Telix shares.

Revenue reached USD 245.00 million

Telix reported group revenue of USD 245.00 million for the third quarter of 2026, compared with USD 206.00 million in the third quarter of 2025. That represents growth of 19.00 percent year over year. Precision Medicine revenue increased 30.00 percent to USD 201.00 million, while Telix Manufacturing Solutions revenue declined 6.00 percent to USD 44.00 million, according to Telix Pharmaceuticals.

Price and market position

On the Australian Securities Exchange, Telix last traded at AUD 12.79 on October 27, 2026 at 4:12 p.m. AEDT. The same session showed a 52-week range of AUD 8.26 to AUD 18.22 and a market capitalization of AUD 4.3 billion. Telix's Australian listing and Nasdaq listing are identified on its investor-relations page.

Valuation and upcoming dates

MarketScreener reports an average analyst target of AUD 24.17 and 12 analysts in its October 2026 consensus. The target lies 89.05 percent above the Australian share price of AUD 12.79. Telix also reaffirmed that fiscal year 2026 revenue and other income is expected to exceed USD 1.00 billion, with revenue tracking toward the upper end of guidance of USD 950.00 million to USD 970.00 million plus USD 40.00 million of other income.

What the meeting date changes

For investors, December 1 is the next clearly dated corporate checkpoint. The October 21 release also set research and development spending guidance at USD 240.00 million to USD 260.00 million, compared with the previous range of USD 230.00 million to USD 270.00 million. That narrower range and the scheduled shareholder vote provide two concrete reference points ahead of the meeting.

Stock remains tied to company milestones

Telix combines commercial imaging revenue with development programs and manufacturing capacity. The third-quarter figures show that Precision Medicine contributed USD 201.00 million of the USD 245.00 million group total, while the December meeting places the proposed merger on the corporate calendar. Telix stock was trading at EUR 8.13 at Lang & Schwarz on October 27, 2026 at 7:26 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Telix stock.